Intervention

non-interventional

ClinicalTrials.gov intervention label

Clinical trials8

Recruiting0

Common conditions18

Lead sponsors shown7

Clinical trials

8 shown

Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + FulvestrantNCT07008963 · 2025-07-31

The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical SettingNCT07021443 · 2023-10-09

Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult PatientsNCT04492384 · 2020-06-29

Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast CancerNCT04158505 · 2020-02-28

Blood Pressure Variability and Cardiovascular Disease Events in Patients With HypertensionNCT04342468 · 2017-07-14

Palbociclib in Real World PracticeNCT03280303 · 2017-01-04

A Non-Interventional Follow Up Study For Subjects Who Received Sildenafil for Persistent Pulmonary Hypertension of the Newborn (PPHN)NCT01801982 · 2012-11-01

Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and OverweightNCT00584519 · 2007-06-01

Common conditions

Cardiovascular Diseases2 Hypertension2 Metastatic Breast Cancer2 Advanced Breast Cancer1 Blood Pressure Variability1 Cardiac Event1 CKD1 Copd1 Coronary Heart Disease1 Covid191 Diabetes1 HER2-positive Breast Cancer1 Non-Alcoholic Fatty Liver Disease1 Overweight and Obesity1 Pneumonia1 Pulmonary Hypertension, Persistent, of the Newborn1 SARS-CoV-2 Infection1 Schizophrenia1

Leading sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.2 AstraZeneca1 Chinese Academy of Medical Sciences1 Eurasian Association of Therapists1 Pfizer1 Universitair Ziekenhuis Brussel1 University of Malaya1

Trial status mix

COMPLETED7

UNKNOWN1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.